|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral capsule
|
|
gptkbp:approves
|
gptkb:2007
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Vyvanse
|
|
gptkbp:casnumber
|
608137-00-4
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C15 H25 N3 O
|
|
gptkbp:class
|
Schedule II controlled substance
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
hyperthyroidism
history of drug abuse
cardiovascular disorders
|
|
gptkbp:duration
|
up to 14 hours
as prescribed by a doctor
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:capsule
chewable tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lisdexamfetamine
|
|
gptkbp:ingredients
|
gptkb:lisdexamfetamine_dimesylate
|
|
gptkbp:interacts_with
|
MAO inhibitors
antihypertensives
other stimulants
|
|
gptkbp:is_involved_in
|
gptkb:children
adults
adolescents
|
|
gptkbp:is_monitored_by
|
regular follow-up required
|
|
gptkbp:lifespan
|
10 to 13 hours
|
|
gptkbp:marketed_as
|
gptkb:Shire_Pharmaceuticals
|
|
gptkbp:mechanism_of_action
|
increases levels of norepinephrine and dopamine
|
|
gptkbp:metabolism
|
gptkb:dextroamphetamine
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
potential for abuse
may cause cardiovascular events
may exacerbate psychiatric disorders
|
|
gptkbp:side_effect
|
anxiety
nausea
insomnia
dry mouth
loss of appetite
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:symptoms
|
gptkb:depression
fatigue
sleep disturbances
|
|
gptkbp:titration
|
dose adjustment required
|
|
gptkbp:used_for
|
treatment of ADHD
treatment of binge eating disorder
|
|
gptkbp:bfsParent
|
gptkb:Vyvanse
|
|
gptkbp:bfsLayer
|
6
|